|Day Low/High||52.48 / 53.70|
|52 Wk Low/High||38.48 / 61.71|
I have been accumulating a position in SPDR S&P Biotech ETF . Pfizer's proposed acquisition for Biohaven Pharmaceutical (+73% in after hours) may help the effort today. I plan to add to XBI and FibroGen today (good results).
There will have to be an adjustment made to their Covid vaccine and others at some point.
Upside - +12% (receives FCC license for US-based testing of BlueWalker 3 satellite) - +9.5% (Activist Elliott sends letter to the Board of Western Digital; Offers $1B+ of incremental equity capital to facilitate separation of Flash business) - +9.3...
The CSI 300 plunged to its lowest level in two years as residents of the Chinese capital stripped grocery store shelves bare amid lockdown fears.
The market roared, but the pros did not tag along in size. They either have to catch up, or they are just not coming.
Here's where I think MRK can go and how to play it.
The growth crowd has moved on, leaving a stock trading at attractive levels.
You might not immediately think of this name as a big winner over the last two years.
The Nasdaq Composite suffered a 'death cross' back in mid-February and what happened after that is now clear to see.
It appears that miners, drillers and defense contractors are still the places to be from an equity perspective. Everything else is a trade.
Selections from next week's lineup of events: Monday Kohl's virtual investor day. Pfizer participates in Cowen's 42nd Annual Healthcare Conference. Tuesday Parker Hannifin virtual meeting with investors and analysts. Microsoft participates at ...
I had actually worried a bit that Arm was going to take Jensen Huang's eye off of the ball. That worry can now be put to bed.
Investment experts pick their favorites in the sector for 2022, ranging from diagnostics to medical devices and medical marijuana to drug development.
In short, Friday was simply an absolute disaster for the U.S. in macroeconomic terms.
Seven investment experts participating in Moneyshow's Top Picks 2022 report share their ideas for healthy portfolio gains in 2022.
Negative returns for 2022? It's a midterm election year. We will see increased volatility. Anything is possible, and it would not surprise me.
Friday might be a market holiday, but it became obvious on Wednesday that trading volumes had started to truly dwindle.
Mirum Pharmaceuticals and TG Therapeutics are undervalued as stand-alone entities, but also would make easy and logical targets for a larger player.
Perhaps the rally had been set up by the depth of the pressure placed on financial markets over the prior three days. Perhaps.
Bear in mind that as Omicron threatens to, and will to some degree, slow economic activity, the real catalyst will be the political and policy response.
Markets ended mixed for the day as options expire. Pfizer continues to pick up bulls, it seems. Cantor Fitzgerald believes the company's Covid-19 vaccine and hotly anticipated antiviral drug could generate combined peak sales of between $50 billion ...
Market has not moved much since our last update. Biotech continues to be one of the strongest sectors today with the SPDR S&P Biotech ETF up nearly 5% on the day. It will be interesting to see if biotech can hold its gains into the close given it i...
Looks like we are going to open the last day of what has been a miserable week for the markets in the red, based on where futures are currently trading. Small-caps, once again, look like they will take the brunt of the early decline. Skyworks Soluti...
We have new price targets for soaring shares of PFE. Let's check the charts.
Two recent acquisition deals and big drug companies that are flush with cash provide reason to believe biotech stocks could rebound in 2022
The top-10 holdings of Kevin O'Leary's O'Shares FTSE U.S. Quality Dividend ETF are an interesting source of quality dividend growth stocks.